In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals Shaping the Medical Industry (03/2011)

Executive Summary

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions.

You may also be interested in...



UK Avoids 'Cliff Edge' By Extending EU Drug Approval Reliance Procedure

The UK drugs regulator says it needs to make sure that companies do not “deprioritize” GB approval applications while a new “international reliance framework” is being developed.

New UK Health Secretary Wants More OTCs Available And Greater Role For Pharmacists

More medicines available without a prescription and more responsibility for community pharmacists are two of the goals set out by the UK's new Secretary of State for Health and Social Care.

Allogene Frustrated By FDA’s Delayed CAR-T Trial Review

Allogene hopes its off-the-shelf CAR-T can begin a potentially pivotal Phase II study by the end of this year but is frustrated by an “under-resourced and overworked FDA.”

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

IV003608

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel